Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Cediranib + Olaparib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Cediranib||AZD-2171|Recentin|AZD2171|AZD 2171||KIT Inhibitor 51 VEGFR1 Inhibitor 5 VEGFR2 Inhibitor 35 VEGFR3 Inhibitor 5||Cediranib (AZD-2171) is an ATP-competitive inhibitor of all three vascular endothelial growth factor receptors (FLT1, KDR, and FLT4) and KIT, thereby blocking VEGF-signaling, angiogenesis, and tumor cell growth (PMID: 15899831, PMID: 24714778, PMID: 32444417).|
|Olaparib||Lynparza||AZD2281|KU-0059436||PARP Inhibitor (Pan) 20||Lynparza (olaparib) binds to and inhibits PARP, resulting in inhibition of DNA repair and lethality in homologous-recombination deficient cells, and may be a sensitizing agent for chemotherapy and radiotherapy (PMID: 25028150, PMID: 24225019). Lynparza (olaparib) is FDA approved for treatment of ERBB2 (HER2)-negative breast cancer with deleterious or suspected deleterious germline BRCA mutations, ovarian cancer with deleterious or suspected deleterious germline BRCA mutations and received 3 or more prior therapies, metastatic pancreatic adenocarcinoma with deleterious or suspected deleterious germline BRCA mutations as a maintenance therapy, metastatic castration-resistant prostate cancer with deleterious or suspected deleterious germline or somatic homologous recombination repair gene mutations who progressed following enzalutamide or abiraterone, as a maintenance therapy in recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer and in epithelial ovarian, fallopian tube or primary peritoneal cancer with deleterious or suspected deleterious germline or somatic BRCA mutation, and in combination with Avastin (bevacizumab) as maintenance therapy in HDR defective epithelial ovarian, fallopian tube or primary peritoneal cancer as defined by deleterious or suspected deleterious BRCA mutation, and/or genomic instability (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||ovary serous adenocarcinoma||not applicable||Cediranib + Olaparib||Phase II||Actionable||In a Phase II trial, Cediranib (AZD-2171) and Lynparza (olaparib) treatment was well-tolerated, and resulted in an objective response (OR) of 9% (all partial), a 16-week progression-free survival (PFS) of 47%, and a disease control rate (DCR) of 68% in serous ovarian cancer patients (n=34), with an OR of 0%, 20%, 8%, 16-week PFS of 55%, 50%, 39%, and a DCR of 82%, 60%, 62% in platinum-sensitive (n=11), platinum-resistant (n=10), and exploratory cohorts (n=13), respectively (PMID: 32444417; NCT02681237).||32444417|
|Unknown unknown||ovarian cancer||not applicable||Cediranib + Olaparib||Phase I||Actionable||In a Phase I clinical trial, the combination therapy of Cediranib (AZD-2171) and Lynparza (olaparib) demonstrated safety and efficacy in patients with ovarian cancer (J Clin Oncol 32:5s, 2014 (suppl; abstr LBA5500)).||detail...|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT02681237||Phase I||Cediranib + Olaparib||A Study of Cediranib and Olaparib at Disease Worsening in Ovarian Cancer||Active, not recruiting|
|NCT02340611||Phase II||Cediranib + Olaparib||A Study of Cediranib and Olaparib at the Time Ovarian Cancer Worsens on Olaparib||Completed|
|NCT02893917||Phase II||Cediranib + Olaparib Olaparib||Olaparib With or Without Cediranib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer||Active, not recruiting|
|NCT02899728||Phase II||Carboplatin + Cisplatin + Etoposide Cediranib + Olaparib||Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer||Terminated|
|NCT03660826||Phase II||Olaparib Cediranib + Olaparib||Olaparib and Cediranib Maleate in Treating Patients With Recurrent, Refractory, or Metastatic Endometrial Cancer||Suspended|
|NCT02498613||Phase II||Cediranib + Olaparib||A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors||Recruiting|
|NCT02345265||Phase II||Cediranib + Olaparib||Olaparib and Cediranib Maleate in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer||Active, not recruiting|
|NCT02446600||Phase III||Cediranib + Olaparib Olaparib Carboplatin + Gemcitabine + Paclitaxel + Pegylated liposomal-doxorubicin||Olaparib or Cediranib Maleate and Olaparib Compared With Standard Platinum-Based Chemotherapy in Treating Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer||Active, not recruiting|
|NCT02974621||Phase II||Bevacizumab Cediranib + Olaparib||Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma||Active, not recruiting|
|NCT04090567||Phase II||Cediranib + Olaparib AZD6738 + Olaparib||Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer||Recruiting|
|NCT02889900||Phase II||Cediranib + Olaparib||Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum-Resistant Ovarian Cancer (CONCERTO)||Active, not recruiting|
|NCT01116648||Phase Ib/II||Olaparib Cediranib + Olaparib||Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer||Active, not recruiting|